Overview
To evaluate the efficacy and safety of sintilimab combined with bevacizumab and liver protective support therapy in Child-Pugh B and/or ECOG PS 2 unresectable hepatocellular carcinoma
Eligibility
Inclusion Criteria:
- Advanced unresectable hepatocellular carcinoma confirmed by histology or cytology
- Age 20-79
- At least one measurable lesion defined in RECIST version 1.1
- Child Pugh grade B
- ECOG PS score 2
- The expected life is at least 90 days
Exclusion Criteria:
- Previously received anti-PD-1, PD-L1, PD-L2, CD137, CTLA-4 antibody treatment, or any other treatment that regulates T cells
- Received systemic corticosteroid or immunosuppressive therapy within 28 days before enrollment
- Complicated with autoimmune diseases or having a history of chronic or recurrent autoimmune diseases
- History of pleural or pericardial adhesions within 28 days before enrollment
- HIV antibody, HTV-Ⅰantibody, HCV antibody, hepatitis B surface protein antigen, hepatitis B surface protein antibody, hepatitis B core protein antibody or any detectable hepatitis B virus DNA test results were positive
- Multiple primary cancers (excluding completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, superficial bladder cancer, and any other cancer that has not recurred for at least 5 years)
- Brain or meningeal metastasis (unless asymptomatic and does not require treatment)
- Uncontrollable or serious cardiovascular disease.